HHS Moves to Strip Certification of Major Organ Donation Network Over Safety Failures

How Systemic Failures at Network for Hope Led to Decertification

The U.S. Department of Health and Human Services on August 5 began the decertification of Network for Hope, the federally designated organ procurement organization (OPO) serving Kentucky and parts of Indiana, Ohio, and West Virginia. The move follows multiple federal reviews that uncovered repeated patient safety failures despite oversight and improvement opportunities.

Between 2021 and 2024, HRSA examined 351 cases where organ donation was authorized but ultimately not completed at Network for Hope. In 103 cases—more than 29%—investigators found concerning features. Most alarming, 73 patients reportedly had neurological signs inconsistent with a diagnosis of death, raising questions about whether organ procurement began before donors were actually deceased. Reviews also pointed to poor neurologic assessments, lack of coordination with medical teams, questionable consent practices, and misclassification of causes of death, particularly in overdose cases.

Despite these findings, the Biden administration did not hold the organization accountable, according to HHS. After HRSA identified ongoing patient safety concerns in 2025 and required a corrective action plan, both HRSA and CMS conducted independent reviews in 2026. Each found that Network for Hope had failed to demonstrate sufficient improvement, leading Secretary Robert F. Kennedy Jr. to initiate the Medicare decertification process. CMS Administrator Dr. Mehmet Oz warned that any provider who cannot safeguard patients will be replaced.

The decertification is part of a larger Trump administration reform of the organ donation system, which includes a strengthened misconduct reporting system, removal of DEI provisions from transplant models, and a mandate that all OPOs appoint a Patient Safety Officer to monitor events in real time.

Why the Decertification Shakes the Organ Transplant Ecosystem

The Severity of the Patient Safety Breaches

The HRSA findings that 73 potential donors may not have been deceased at the time of procurement strike at the core of public trust in organ donation. These are not administrative lapses but evidence that the foundational medical determination—brain death—may have been skipped or mishandled. Misclassification of overdose deaths adds a further layer of vulnerability, as these patients require particularly rigorous assessment. The sheer volume of cases flagged (nearly one in three examined) suggests systemic failures, not isolated mistakes.

Who Is Affected: From Waiting Patients to Donor Families

The immediate impact will be felt by patients awaiting transplants in the affected service area who now face uncertainty about organ recovery continuity. Donor families who believed their loved one’s gift would be handled with utmost care may experience profound betrayal. For the broader transplant ecosystem, the decertification signals that “business as usual” oversight is ending. Hospitals that relied on Network for Hope must scramble to establish new OPO arrangements, potentially causing delays in organ placement.

The Broader Regulatory Crackdown

The Trump administration is using this case to accelerate reform. Alongside the decertification, HHS is requiring every OPO to appoint a Patient Safety Officer with direct reporting authority to HRSA and OPTN, tasked with real-time monitoring and root cause analyses. The removal of DEI provisions from the 2024 IOTA model and the election of an independent OPTN board underscore a shift toward what officials describe as a merit-based, safety-first system. Other OPOs are now on notice: if your internal reviews do not withstand federal scrutiny, you could be next.

What Comes Next for Organ Procurement Organizations Nationwide

Network for Hope’s decertification sets a precedent that CMS will act decisively when patient safety is at stake. Expect heightened audits nationwide, particularly of brain death protocols and adverse event reporting. OPOs that have been slow to adopt rigorous neurological testing standards now face significant regulatory risk. For the organ donation industry, the era of assumed federal tolerance is over.

What Transplant Centers and Organ Procurement Organizations Should Do Now

Transplant centers in the affected region must immediately coordinate with CMS and HRSA to identify interim OPO services and ensure continuity of organ recovery. Delays could cost lives; contingency plans should be activated today.

All organ procurement organizations should conduct an urgent review of their neurological death determination protocols, paying special attention to cases involving suspected overdose, where the HRSA findings indicate the highest risk of misclassification.

Hospital systems that work with OPOs should audit consent practices and require dual-physician confirmation of brain death before any procurement steps begin, addressing the “questionable consent” patterns flagged in the federal reviews.

Donor families and patient advocates can expect temporary disruption in organ availability, but the new Patient Safety Officer mandate creates a direct channel for reporting concerns, which should improve accountability over the long term.